Compounded semaglutide is a non-FDA-approved alternative to products that contain semaglutide, such as Ozempic. Learn how the safety and efficacy of compounded semaglutide compares with Ozempic.

At 3 years, rates of the composite outcomes increased to 5.9% and 6.9% for those treated with semaglutide and empagliflozin, respectively, corresponding to an HR of 0.89 (95% CI, 0.78-1.02).

Semaglutide drugs have grown in popularity, resulting in shortages of Ozempic and Wegovy. To help meet demand, some licensed compounding pharmacies have begun producing compounded semaglutide.

Taking semaglutide may lead to a slight increase in heart rate — typically by two to three beats per minute, based on trials sponsored by Novo Nordisk using 0.5 and 1 mg doses of semaglutide.

Premature permanent discontinuation of oral semaglutide or placebo occurred in 1309 participants (27.1%) in the oral semaglutide group and in 1373 participants (28.5%) in the placebo group (Fig. S3B).

Semaglutide is revolutionizing kidney disease treatment for type 2 diabetes patients. Learn how it works and its potential impact on CKD.

In its declaratory order on semaglutide, FDA clarified that it will exercise enforcement discretion for 503A compounding pharmacies until April 22, 2025, and 503B outsourcing facilities until May ...

Semaglutide, the active ingredient in GLP-1 drugs Ozempic and Wegovy, may help people quit smoking, a new study found. People with type 2 diabetes who smoke who took semaglutide were less likely ...